Oncology ESMO25: The changing landscape of rare oncology, with Jan Ki... ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.
News ASH: AstraZeneca's dual-wielding CAR-T shows promise AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.